Philogen SpA
MIL:PHIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
United Parcel Service Inc
NYSE:UPS
|
US |
|
Starbucks Corp
NASDAQ:SBUX
|
US |
|
R
|
RPM Automotive Group Ltd
ASX:RPM
|
AU |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (11.4), the stock would be worth €17.78 (16% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.5 | €21.05 |
0%
|
| 3-Year Average | 11.4 | €17.78 |
-16%
|
| Industry Average | 14.1 | €21.93 |
+4%
|
| Country Average | 11.2 | €17.41 |
-17%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€524.3m
|
/ |
Jul 2025
€38.9m
|
= |
|
|
€524.3m
|
/ |
Dec 2025
€318.1m
|
= |
|
|
€524.3m
|
/ |
Dec 2026
€59.9m
|
= |
|
|
€524.3m
|
/ |
Dec 2027
€3.7m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IT |
|
Philogen SpA
MIL:PHIL
|
615.5m EUR | 13.5 | 13.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 19.7 | 85.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 14.9 | 19.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 14.7 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 41.9 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.1 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0.9 |
| 30th Percentile | 7.7 |
| Median | 11.2 |
| 70th Percentile | 14.9 |
| Max | 472.1 |
Other Multiples
Philogen SpA
Glance View
Philogen SpA engages engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 135 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The firm's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.
